Abstract
Ranitidine (brand name Zantac) is an H2-receptor antagonist (H2-blocker) commonly used to treat gastroesophageal reflux and peptic ulcer disease. After recent studies showed that ranitidine degrades to form high levels of N-nitrosodimethylamine (NDMA), a potent carcinogen in animal models and probable human carcinogen, 1 Valisure citizen petition on ranitidine. https://www.valisure.com/wp-content/uploads/Valisure-Ranitidine-FDA-Citizen-Petition-v4.12.pdf Google Scholar ,2 Emery Pharma Citizen Petition. https://emerypharma.com/wp-content/uploads/2020/01/EP-Ranitidine-FDA-Citizen-Petition-v21-January-2-2020.pdf Google Scholar the US Food and Drug Administration (FDA) requested that ranitidine sales be halted. 3 FDA requests removal of all ranitidine products (Zantac) from the Market. https://www.fda.gov/news-events/press-announcements/fda-requests-removal-all-ranitidine-products-zantac-market Google Scholar Because the implications for human carcinogenesis remain unclear, we evaluated the association between ranitidine use and cancer risk in UK Biobank.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
